Drug makers are under fire as the $84,000 price tag on a new hepatitis medicine has galvanized the debate over prescription drug costs. But the pharmaceutical industry could be mounting a much stronger defense if it weren’t haunted by its support for government health care.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.